JP2006519160A - 抗原性ペプチド - Google Patents

抗原性ペプチド Download PDF

Info

Publication number
JP2006519160A
JP2006519160A JP2004541361A JP2004541361A JP2006519160A JP 2006519160 A JP2006519160 A JP 2006519160A JP 2004541361 A JP2004541361 A JP 2004541361A JP 2004541361 A JP2004541361 A JP 2004541361A JP 2006519160 A JP2006519160 A JP 2006519160A
Authority
JP
Japan
Prior art keywords
peptide
independently
group
library
peptide library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004541361A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006519160A5 (cg-RX-API-DMAC7.html
Inventor
アミル ザキエビッチ マクシュトボ,
アレクサンダー ボリソビッチ リジコブ,
アレクサンダー アレクサンドロビッチ コロボブ,
ザキ アミロビッチ マクシュトブ,
Original Assignee
ステイト リサーチ センター オブ ビロロジイ アンド バイオテクノロジー “ベクター”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステイト リサーチ センター オブ ビロロジイ アンド バイオテクノロジー “ベクター” filed Critical ステイト リサーチ センター オブ ビロロジイ アンド バイオテクノロジー “ベクター”
Publication of JP2006519160A publication Critical patent/JP2006519160A/ja
Publication of JP2006519160A5 publication Critical patent/JP2006519160A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004541361A 2002-10-03 2003-09-25 抗原性ペプチド Pending JP2006519160A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2002126396/13A RU2237065C2 (ru) 2002-10-03 2002-10-03 Иммуногенная библиотека химерных пептидов, мимикрирующая генетическое многообразие гипервариабельного района v3 белка оболочки gp120 вируса иммунодефицита человека
PCT/RU2003/000421 WO2004031212A1 (en) 2002-10-03 2003-09-25 Antigenic peptides

Publications (2)

Publication Number Publication Date
JP2006519160A true JP2006519160A (ja) 2006-08-24
JP2006519160A5 JP2006519160A5 (cg-RX-API-DMAC7.html) 2007-02-01

Family

ID=32067104

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004541361A Pending JP2006519160A (ja) 2002-10-03 2003-09-25 抗原性ペプチド

Country Status (10)

Country Link
US (1) US20060153865A1 (cg-RX-API-DMAC7.html)
EP (1) EP1558628A4 (cg-RX-API-DMAC7.html)
JP (1) JP2006519160A (cg-RX-API-DMAC7.html)
KR (1) KR20050067411A (cg-RX-API-DMAC7.html)
CN (1) CN1714100A (cg-RX-API-DMAC7.html)
AU (1) AU2003269748A1 (cg-RX-API-DMAC7.html)
CA (1) CA2500401A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ539606A (cg-RX-API-DMAC7.html)
RU (1) RU2237065C2 (cg-RX-API-DMAC7.html)
WO (2) WO2004031212A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530356A (ja) * 2007-03-27 2010-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 急性伝染hivエンベロープ・サイン
JP2022538433A (ja) * 2019-06-27 2022-09-02 ロシュ シークエンシング ソリューションズ,インコーポレイティド 増強された部分配列多様性を有するペプチドライブラリ及びその使用方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006227380B2 (en) * 2005-03-17 2012-08-16 Vel Partners Holdings Llc Immunogens for vaccines against antigenically variable pathogens and diseases
WO2007079755A1 (en) 2006-01-12 2007-07-19 Janus Beierholm Holding Aps Reimmunization and antibody design
PL2027158T3 (pl) * 2006-05-02 2013-02-28 Carviar Aps Sposób immunizacji gatunków ptaków
WO2008153925A2 (en) * 2007-06-06 2008-12-18 Danisco Us, Inc., Genencor Division Methods for improving multiple protein properties
US20100215695A1 (en) * 2007-10-09 2010-08-26 Technologie Integrale Limited Hiv preventive vaccine based on hiv specific antibodies
BR122020015754B8 (pt) 2008-12-05 2021-04-06 Takeda Vaccines Inc métodos para aumentar a taxa de crescimento viral, para aumentar o tamanho da placa de uma cultura viral, para reduzir o tempo de latência do crescimento de uma cultura viral, e para a cultura de vírus para a produção e fabricação
WO2011138032A2 (en) * 2010-05-05 2011-11-10 Artemev, Timur Universal influenza vaccines and methods for their generation
EP2422618A1 (en) * 2010-08-27 2012-02-29 Technologie Integrale Ltd. Animal model for the evaluation of the efficacy of an HIV vaccine
EP2492279A1 (en) * 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Rapid immunogen selection method using lentiviral display
WO2013040040A1 (en) * 2011-09-12 2013-03-21 New York University School Of Medicine Peptides mimicking hiv-1 viral epitopes in the v2 loop for the gp120 surface envelope glycoprotein
US10383927B2 (en) 2015-01-09 2019-08-20 Primex Clinical Laboratories, Inc. Variable epitope library compositions and methods of therapeutic and prophylactic use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0728015B1 (en) * 1992-06-18 2006-03-08 Creagen, Inc. Method of producing a set of combinatorial polypeptide antigens
WO1994028929A1 (en) * 1993-06-07 1994-12-22 Genentech, Inc. Hiv envelope polypeptides
GB2282378A (en) * 1993-09-30 1995-04-05 Merck & Co Inc Conjugates of epitopes of HIV with a protein complex from Neisseria
EP0725838A4 (en) * 1993-10-26 1997-02-26 United Biomedical Inc STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS
IT1277057B1 (it) * 1995-12-11 1997-11-04 Tecnogen Scpa Peptidi antigenici migliorati
WO2003066090A1 (en) * 2002-02-08 2003-08-14 Variation Biotechnologies Inc. Immunogenic formulations of variable peptidic epitopes and process for preparation thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530356A (ja) * 2007-03-27 2010-09-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 急性伝染hivエンベロープ・サイン
JP2022538433A (ja) * 2019-06-27 2022-09-02 ロシュ シークエンシング ソリューションズ,インコーポレイティド 増強された部分配列多様性を有するペプチドライブラリ及びその使用方法
US12595591B2 (en) 2019-06-27 2026-04-07 Roche Sequencing Solutions, Inc. Peptide libraries having enhanced subsequence diversity and methods for use thereof

Also Published As

Publication number Publication date
CN1714100A (zh) 2005-12-28
EP1558628A4 (en) 2006-05-31
CA2500401A1 (en) 2004-04-15
RU2237065C2 (ru) 2004-09-27
KR20050067411A (ko) 2005-07-01
WO2004031212A1 (en) 2004-04-15
US20060153865A1 (en) 2006-07-13
NZ539606A (en) 2008-08-29
WO2004031226A1 (fr) 2004-04-15
AU2003269748A1 (en) 2004-04-23
EP1558628A1 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
CN1111540C (zh) 串联的合成hiv-1肽类
TWI232108B (en) Synthetic peptide vaccines for foot-and-mouth disease
JPH0762031B2 (ja) エイズウイルスおよびエイズウイルスのタンパク質に対する細胞性免疫を誘導する合成ペプチド
US20020182222A1 (en) HIV vaccine candidate peptides
JP5946766B2 (ja) Hivワクチン組成物における使用又は診断手段としての使用のためのhiv関連ペプチドの組合せ又は融合物
JP2003529319A (ja) HIV−1gp41を標的化する広範に中和する抗体を誘発する方法
JPH05500517A (ja) 後天性免疫不全症候群の予防および治療
JP2006056893A (ja) Hivに対する中和性抗体および細胞障害性tリンパ球を誘発する複合合成ペプチド構築物
JP2569185B2 (ja) 抗hiv応答を喚起する合成抗原
Berzofsky Development of artificial vaccines against HIV using defined epitopes
JP2002533125A (ja) 改変hivenvポリペプチド
WO2001055177A2 (en) Methods to identify ctl epitopes of hiv
US7118874B2 (en) Immunogenic formulation and process for preparation thereof
WO2022003119A1 (en) Cross-reactive coronavirus vaccine
US20060153865A1 (en) Antigenic peptides
US5081226A (en) Synthetic peptides sharing sequence homology with the HIV envelope protein
US6210873B1 (en) Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
Berzofsky Mechanisms of T cell recognition with application to vaccine design
US7319000B1 (en) Compositions and methods for eliciting immune or anti-infective responses
AU666160B2 (en) Compositions for eliciting cytotoxic T-lymphocyte responses against viruses
Berzofsky Features of T-cell recognition and antigen structure useful in the design of vaccines to elicit T-cell immunity
AU2002231510B2 (en) Immunogenic formulations of variable peptidic epitopes and process for preparation thereof
JP2004535369A (ja) 試薬およびワクチンとして使用するための免疫原性hivペプチド
Berzofsky Structural features of T-cell recognition: applications to vaccine design
ZA200405492B (en) Immunogenic formulations of variable peptidic epitopes and process for preparation thereof.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090721

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100112